Magenta Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the closing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses, are approximately $100,000,000. In addition, the underwriters have a 30-day option to purchase up to 1,000,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. Magenta Therapeutics’ common stock began trading on the Nasdaq Global Market on June 21, 2018 under the symbol “MGTA.”

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from:

• J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204
• Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]
• Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, telephone: 631-274-2806.

Important InformationA registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (“SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Magenta TherapeuticsHeadquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180625006210/en/

Magenta Therapeutics:
Manisha Pai, 857-242-1155
Vice President, Communications & Investor Relations
[email protected]

Source: Magenta Therapeutics, Inc.

You May Also Be Interested In

• Singularity Future Technology closes $1.8M registered direct offering
• Andersen prices secondary offering of 4.28M shares at $44 each
• Zipalertinib trial data to be presented at IASLC lung cancer conference